135 related articles for article (PubMed ID: 22248343)
1. Pharmacokinetic evaluation of axitinib.
Patson B; B Cohen R; Olszanski AJ
Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):259-70. PubMed ID: 22248343
[TBL] [Abstract][Full Text] [Related]
2. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
3. Axitinib for the treatment of advanced non-small-cell lung cancer.
King JW; Lee SM
Expert Opin Investig Drugs; 2013 Jun; 22(6):765-73. PubMed ID: 23452008
[TBL] [Abstract][Full Text] [Related]
4. Axitinib (AG-013736).
Kelly RJ; Rixe O
Recent Results Cancer Res; 2010; 184():33-44. PubMed ID: 20072829
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
6. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
7. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
[TBL] [Abstract][Full Text] [Related]
9. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
10. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
Bracarda S; Castellano D; Procopio G; SepĂșlveda JM; Sisani M; Verzoni E; Schmidinger M
Expert Opin Drug Saf; 2014 Apr; 13(4):497-510. PubMed ID: 24641566
[TBL] [Abstract][Full Text] [Related]
11. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Orillard E; Mouillet G; Calcagno F; Devillard N; Bouchet S; Royer B
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1273-1276. PubMed ID: 28451830
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Locati LD; Licitra L; Agate L; Ou SH; Boucher A; Jarzab B; Qin S; Kane MA; Wirth LJ; Chen C; Kim S; Ingrosso A; Pithavala YK; Bycott P; Cohen EE
Cancer; 2014 Sep; 120(17):2694-703. PubMed ID: 24844950
[TBL] [Abstract][Full Text] [Related]
14. Axitinib, a new therapeutic option in renal cell carcinoma.
Kessler ER; Bowles DW; Flaig TW; Lam ET; Jimeno A
Drugs Today (Barc); 2012 Oct; 48(10):633-44. PubMed ID: 23110259
[TBL] [Abstract][Full Text] [Related]
15. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
16. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
[TBL] [Abstract][Full Text] [Related]
17. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri TK
Curr Opin Investig Drugs; 2008 Jun; 9(6):658-71. PubMed ID: 18516765
[TBL] [Abstract][Full Text] [Related]
18. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
Garrett M; Taylor T; Mould DR; Amantea MA; Chen Y; Ingrosso A; Pithavala YK
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1131-1141. PubMed ID: 27783139
[TBL] [Abstract][Full Text] [Related]
20. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
Chen Y; Rini BI; Motzer RJ; Dutcher JP; Rixe O; Wilding G; Stadler WM; Tarazi J; Garrett M; Pithavala YK
Target Oncol; 2016 Apr; 11(2):229-34. PubMed ID: 26400730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]